Previous Close | $4.76 |
AI Value | $72.34 |
Upside potential | +1,420% |
Altimmune, Inc. (ALT) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, liver diseases, and other metabolic disorders. The company's lead candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist in Phase 2 trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH). Altimmune operates in the highly competitive obesity and liver disease markets, where it faces established players like Novo Nordisk and Eli Lilly. Its competitive advantage lies in pemvidutide's potential for superior weight loss efficacy and tolerability compared to existing GLP-1 therapies, as suggested by early clinical data.
Pemvidutide's dual mechanism of action (GLP-1 + glucagon) differentiates it from single-target competitors. Altimmune holds exclusive rights to its peptide technology platform.
Altimmune offers high-risk, high-reward exposure to the obesity/MASH markets through pemvidutide. The stock is a binary play on upcoming clinical data - positive results could drive significant upside, while failures may render the pipeline obsolete. Suitable only for risk-tolerant investors with a 3-5 year horizon. Key monitoring points: pemvidutide's weight loss efficacy vs. competitors (15%+ body weight reduction desirable) and liver fat reduction in MASH.
Company SEC filings (10-K/Q), clinicaltrials.gov, EvaluatePharma market projections, analyst reports from Jefferies/William Blair.
Historical valuation data is not available at this time.